Literature DB >> 3127419

Differential effects of feeding on the ultradian variation of the growth hormone (GH) response to GH-releasing hormone in normal subjects and patients with obesity and anorexia nervosa.

L De Marinis1, G Folli, C D'Amico, A Mancini, P Sambo, A Tofani, A Oradei, A Barbarino.   

Abstract

Nutritional status and metabolic fuels are factors involved in the regulation of GH secretion and GH responses to GHRH. The effects of feeding on GHRH-induced GH release were studied in 13 normal women, 14 obese women, and 9 women with anorexia nervosa. GHRH-(1-44) (50 micrograms, iv) was administered at 0900 h after an overnight fast or at 1300 h after a normal meal at 0800 h, and at the same times 45 min after a 800-Cal meal on different days. The mean peak plasma GH responses to GHRH administered before a meal at 0900 h were 52.8 +/- 5.6 (+/- SE) micrograms/L in normal women, 8.2 +/- 1.3 micrograms/L in obese women, and 53.2 +/- 7.7 micrograms/L in anorexic women. When GHRH was administered before a meal at 1300 h, the mean peak plasma GH levels were lower than those at 0900 h; this reduction was -64.2% in normal women, -64.9% in obese women, and -55.8% in women with anorexia nervosa. After feeding, the plasma GH responses to GHRH were blunted in normal women at 0900 h (-60.9%) and 1300 h (-34.6%) compared with the fasting peak responses. In obese women the plasma GH response to GHRH after feeding was increased compared with that when these women had fasted (+60% at 0900 h and +406.9% at 1300 h). Finally, differential effects of feeding were present in anorexic women; the response was lower at 0900 h (-46.4%) and greater at 1300 h (+50.8%). We conclude that there is an ultradian variation in GHRH-stimulated GH secretion and that the responses differ according to nutritional status and body weight.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3127419     DOI: 10.1210/jcem-66-3-598

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Development of acromegaly in a patient with anorexia nervosa: pathogenetic and diagnostic implications.

Authors:  E de Menis; M Gola; A Giustina
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

2.  Increased lipid and lipoprotein concentrations in anorexia nervosa: A systematic review and meta-analysis.

Authors:  Alia A Hussain; Christopher Hübel; Mathias Hindborg; Emilie Lindkvist; Annie M Kastrup; Zeynep Yilmaz; René K Støving; Cynthia M Bulik; Jan M Sjögren
Journal:  Int J Eat Disord       Date:  2019-03-28       Impact factor: 4.861

Review 3.  Role of growth hormone in chronic heart failure. Therapeutic implications.

Authors:  M Volterrani; F Manelli; M Cicoira; R Lorusso; A Giustina
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

4.  Prolonged treatment with glycerophosphocholine, an acetylcholine precursor, does not disclose the potentiating effect of cholinesterase inhibitors on GHRH-induced somatotroph secretion in anorexia nervosa.

Authors:  S Fassino; F Lanfranco; G Abbate Daga; V Mondelli; S Destefanis; G G Rovera; F Camanni; E Ghigo; E Arvat; L Gianotti
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

Review 5.  The effects of exercise on growth.

Authors:  K T Borer
Journal:  Sports Med       Date:  1995-12       Impact factor: 11.136

6.  Infections after transcatheter versus surgical aortic valve replacement: mid-term results of 200 consecutive patients.

Authors:  Sharaf-Eldin Shehada; Daniel Wendt; Davina Peters; Fanar Mourad; Philipp Marx; Matthias Thielmann; Philipp Kahlert; Alexander Lind; Rolf-Alexander Janosi; Tienush Rassaf; Peter-Michael Rath; Martin Thoenes; Heinz Jakob; Mohamed El Gabry
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

7.  GH peak response to GHRH-arginine: relationship to insulin resistance and other cardiovascular risk factors in a population of adults aged 50-90.

Authors:  John D Carmichael; Ann Danoff; Daniela Milani; Ronenn Roubenoff; Martin L Lesser; Elayne Livote; Richard E Reitz; Steven Ferris; David L Kleinberg
Journal:  Clin Endocrinol (Oxf)       Date:  2006-08       Impact factor: 3.478

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.